Search

Laboratorios Farmaceuticos Rovi SA

Închisă

SectorSănătate

61.9 -2.21

Rezumat

Modificarea prețului

24h

Curent

Minim

61.2

Maxim

62.75

Indicatori cheie

By Trading Economics

Venit

3.9M

27M

Vânzări

4.8M

160M

P/E

Medie Sector

24.691

37.003

EPS

0.423

Randament dividend

1.45

Marjă de profit

16.767

Angajați

2,188

EBITDA

4.2M

35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+27.83% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.45%

2.25%

Următoarele câștiguri

6 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

450M

3.3B

Deschiderea anterioară

64.11

Închiderea anterioară

61.9

Sentimentul știrilor

By Acuity

50%

50%

176 / 373 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 oct. 2025, 23:28 UTC

Acțiuni populare

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 oct. 2025, 23:07 UTC

Câștiguri

Prudential PLC 3Q New Business Profit Up 13%

30 oct. 2025, 00:00 UTC

Câștiguri

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 oct. 2025, 00:00 UTC

Câștiguri

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 oct. 2025, 00:00 UTC

Câștiguri

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 oct. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 oct. 2025, 23:40 UTC

Câștiguri

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 oct. 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 oct. 2025, 23:25 UTC

Câștiguri

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 oct. 2025, 22:51 UTC

Câștiguri

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 oct. 2025, 22:45 UTC

Câștiguri

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 oct. 2025, 22:41 UTC

Câștiguri

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 oct. 2025, 22:41 UTC

Câștiguri

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 oct. 2025, 22:09 UTC

Câștiguri

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 oct. 2025, 22:08 UTC

Market Talk
Câștiguri

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 oct. 2025, 21:58 UTC

Câștiguri

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 oct. 2025, 21:58 UTC

Câștiguri

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 oct. 2025, 21:57 UTC

Câștiguri

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 oct. 2025, 21:54 UTC

Câștiguri

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 oct. 2025, 21:46 UTC

Câștiguri

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 oct. 2025, 21:43 UTC

Câștiguri

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 oct. 2025, 21:43 UTC

Câștiguri

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 oct. 2025, 21:42 UTC

Câștiguri

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 oct. 2025, 21:42 UTC

Câștiguri

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 oct. 2025, 21:41 UTC

Câștiguri

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 oct. 2025, 21:41 UTC

Câștiguri

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 oct. 2025, 21:41 UTC

Câștiguri

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 oct. 2025, 21:41 UTC

Câștiguri

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 oct. 2025, 21:40 UTC

Câștiguri

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 oct. 2025, 21:39 UTC

Câștiguri

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

27.83% sus

Prognoză pe 12 luni

Medie 80.85 EUR  27.83%

Maxim 90 EUR

Minim 71.7 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

176 / 373 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat